Table 2

Patient outcomes after 3 years of follow-up

Initial M-arm (n=52)Initial S-arm (n=44)Total (n=96)
Disease activity
 Tender joint count (28 joints)1.8±2.91.1±1.91.47±2.5
 Swollen joint count (28 joints)1.2±2.80.9±2.11.09±2.5
 ESR, mm/first hour18.8±2.816.6±1017.8±15.7
 CRP, mg/L7.4±16,23.6±4.65.6±12.5
 Normal acute-phase reactant, n (%)30 (57.7)24 (54.5)54 (56.2)
 DAS282.7±1.42.6±1.22.6±1.3
Ongoing bDMARD treatment
 ADA, n (%)17 (32.7)13 (29.5)30 (31.2)
 ETA, n (%)24 (46.1)18 (40.9)42 (43.7)
 Other, n (%)8 (15.4)5 (11.4)13 (13.5)
 No bDMARD, n (%)3 (5.8)8 (18.2)11 (11.5)
Ongoing step
 Step 0, n (%)23 (44.2)13 (29.5)36 (37.5)
 Step 1, n (%)5 (9.6)5 (11.4)10 (10.4)
 Step 2, n (%)6 (11.5)6 (13.6)12 (12.5)
 Step 3, n (%)4 (7.7)3 (6.8)7 (7.3)
 Step 4, n (%)3 (5.8)8 (18.2)11 (11.5)
 Switch from initial bDMARD*11 (21.2)9 (20.5)20 (20.8)
 Dose quotient0.74±0.340.58±0.390.66±0.36
 DMARDS combination, n (%)33 (63.5)36 (81.8)69 (71.9)
 MTX combination, n (%)29 (55.8)33 (75)62 (64.6)
 Steroid intake, n (%)4 (7.7)1 (2.3)5 (5.2)
 Structural damage progression, n (%)6/24 (25)7/19 (36.8)13/43 (30.2)
  • Data are presented as mean±SD or n (%).

  • Definition of the steps: ETA 50 mg every 10 days (step 1), 14 days (step 2), 3 weeks (step 3) or stopped (step 4); ADA 40 mg every 21 days (step 1), 28 days (step 2), 6 weeks (step 3) or stopped (step 4).

  • *Treatment switch that occurred between the start of the follow-up and the third year of follow-up.

  • ADA, adalimumab; bDMARD, biological disease-modifying antirheumatic drug; CRP, C reactive protein; DAS, Disease Activity Score; Dose quotient, actual total intake over a month/standard full regimen intake over a month; ESR, erythrocyte sedimentation rate; ETA, etanercept; M-arm, maintenance arm; MTX, methotrexate; S-arm, spacing arm.